The US Food and Drug Administration (FDA) has broadened the approval of Furoscix® (furosemide injection) to treat edema in ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...

Shares Outstanding: 50,095,689 as of December 31, 2024. scPharmaceuticals Inc (NASDAQ:SCPH) reported a significant increase ...

(RTTNews) - scPharmaceuticals Inc. (SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...

We will then open the line for questions. Overall, although we're satisfied with the FUROSCIX commercial growth over the course of 2024, we were especially encouraged by what we saw in Q4 ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31 ...

Management anticipates the Medicare redesign to positively impact FUROSCIX adoption. The redesign reduces patient out-of-pocket costs, which is expected to increase fill rates and demand.